Difference between revisions of "Extranodal NK- and T-cell lymphoma, nasal type"
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
(144 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
+ | {{#lst:Editorial board transclusions|tcl}} | ||
+ | '''Most of these regimens are specific to the nasal type of ENKTCL. For more generic NKTCL regimens, please see [[NK- and T-cell lymphoma|this page]].''' | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: # | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: # | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
+ | =Guidelines= | ||
+ | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
+ | ==[https://www.esmo.org/ ESMO]== | ||
+ | *'''2015:''' d'Amore et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Peripheral-T-Cell-Lymphomas Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/26314772 PubMed] | ||
+ | ==NCCN== | ||
+ | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483 NCCN Guidelines - T-cell Lymphomas].'' | ||
=Untreated= | =Untreated= | ||
− | + | ==Cisplatin & RT {{#subobject:544d0b|Regimen=1}}== | |
− | ==Cisplatin & | + | Cisplatin & RT: Cisplatin & '''<u>R</u>'''adiation '''<u>T</u>'''herapy |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
− | RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy | ||
− | |||
===Regimen {{#subobject:550baf|Variant=1}}=== | ===Regimen {{#subobject:550baf|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2009.23.8592 Kim et al. 2009 (CISL 2004-10-08)] |
− | |style="background-color:# | + | |2006-04 to 2007-10 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | | style="background-color:#e0ecf4" |ORR: 83% | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per | + | *[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 |
− | *Concurrent radiation therapy to the primary tumor, 1.8 to | + | ====Radiotherapy==== |
− | + | *Concurrent [[External_beam_radiotherapy|radiation therapy]] to the primary tumor, 1.8 to 200 cGy fractions (median total dose: 4000 cGy), given 5 times per week. | |
− | '' | + | '''4-week course''' |
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
+ | ====Subsequent treatment==== | ||
+ | *[[#VIPD|VIPD]] consolidation, 3 to 5 weeks after the last dose of cisplatin | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, | + | #'''CISL 2004-10-08:''' Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS; Consortium for Improving Survival of Lymphoma. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009 Dec 10;27(35):6027-32. Epub 2009 Nov 2. [https://doi.org/10.1200/jco.2009.23.8592 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19884539/ PubMed] [https://clinicaltrials.gov/study/NCT00418535 NCT00418535] |
− | + | ==DEP & RT {{#subobject:d8a9eb|Regimen=1}}== | |
− | ==DEP & | + | DEP & RT: '''<u>D</u>'''examethasone, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin), '''<u>R</u>'''adiation '''<u>T</u>'''herapy |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
− | DEP: '''<u>D</u>'''examethasone, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin) | ||
− | |||
− | |||
===Regimen {{#subobject:f93f37|Variant=1}}=== | ===Regimen {{#subobject:f93f37|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1111/ejh.12405 Tsai et al. 2014 (T1405)] |
− | |style="background-color:# | + | |2006-05 to 2009-09 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | | style="background-color:#e0ecf4" |ORR: 81% | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup>/day IV on days 1 to 3 | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3 | |
− | *[[Etoposide (Vepesid)]] | + | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1 |
− | *[[Cisplatin (Platinol)]] | + | ====Radiotherapy==== |
− | *Concurrent radiation therapy to the primary tumor | + | *Concurrent [[External_beam_radiotherapy|radiation therapy]] to the primary tumor: 5040 cGy in 28 fractions |
− | + | '''28-day cycle for 2 cycles''' | |
− | '''28-day cycle | + | </div> |
− | + | <div class="toccolours" style="background-color:#cbd5e7"> | |
− | + | ====Subsequent treatment==== | |
− | + | *[[#VIPD|VIPD]] consolidation | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7. Epub 2014 Oct 10. [ | + | #'''T1405:''' Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7. Epub 2014 Oct 10. [https://doi.org/10.1111/ejh.12405 link to original article] '''contains dosing details on CT.gov''' [https://pubmed.ncbi.nlm.nih.gov/24957163/ PubMed] [https://clinicaltrials.gov/study/NCT00292695 NCT00292695] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
+ | ==DeVIC & RT {{#subobject:4b25e6|Regimen=1}}== | ||
+ | DeVIC & RT: '''<u>De</u>'''xamethasone, '''<u>V</u>'''P-16 (Etoposide), '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>R</u>'''adiation '''<u>T</u>'''herapy | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:74ecfd|Variant=1}}=== | ===Regimen {{#subobject:74ecfd|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2009.23.8295 Yamaguchi et al. 2009 (JCOG0211)] |
− | |style="background-color:# | + | |2003-09 to 2006-12 |
+ | |style="background-color:#91cf61"|Phase 1/2 | ||
+ | | style="background-color:#e0ecf4" |ORR: 81% | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: this is the recommended dose level used in the phase 2 portion.'' | |
− | ==== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
+ | ====Glucocorticoid therapy==== | ||
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 3 | *[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 3 | ||
− | + | ====Chemotherapy==== | |
− | + | *[[Etoposide (Vepesid)]] 67 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3, 22 to 24, 43 to 45 | |
− | + | *[[Ifosfamide (Ifex)]] 1000 mg/m<sup>2</sup> IV over 3 hours once per day on days 1 to 3, 22 to 24, 43 to 45 | |
− | + | *[[Carboplatin (Paraplatin)]] 200 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 22, 43 | |
− | ==== | + | ====Supportive therapy==== |
− | + | *[[Filgrastim (Neupogen)]] (dose/route/schedule not specified) started for WBC count less than 2 x 10<sup>9</sup>/L or ANC less than 1000/μL; discontinued if WBC count more than 5 x 10<sup>9</sup>/L | |
− | *[[Etoposide (Vepesid)]] | + | ====Radiotherapy==== |
− | *[[Ifosfamide (Ifex)]] | ||
− | *[[Carboplatin (Paraplatin)]] | ||
− | |||
− | ====Supportive | ||
− | *[[Filgrastim (Neupogen)]] (dose/route/schedule not specified) started for | ||
− | |||
− | |||
− | |||
− | ==== | ||
''Started simultaneously with the beginning of cycle 1 of chemotherapy'' | ''Started simultaneously with the beginning of cycle 1 of chemotherapy'' | ||
− | *Stage IE | + | *Concurrent [[External_beam_radiotherapy|radiation therapy]] by the following stage-based criteria: |
− | *Stage IIE | + | **Stage IE: 200 cGy fractions x 25 fractions (total dose: 5000 cGy) |
+ | **Stage IIE: 180 cGy fractions x 28 fractions (total dose: 5040 cGy) | ||
+ | '''9-week course''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009 Nov 20;27(33):5594-600. [ | + | # '''JCOG0211:''' Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009 Nov 20;27(33):5594-600. Epub 2009 Oct 5. [https://doi.org/10.1200/jco.2009.23.8295 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19805668/ PubMed] |
− | ## '''Update:''' Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Hotta T, Tsukasaki K, Oshimi K. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012 Nov 10;30(32):4044-6. Epub 2012 Oct 8. [ | + | ## '''Update:''' Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Hotta T, Tsukasaki K, Oshimi K. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012 Nov 10;30(32):4044-6. Epub 2012 Oct 8. [https://doi.org/10.1200/jco.2012.45.6541 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23045573/ PubMed] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | == | + | ==GELOX/RT {{#subobject:e51517|Regimen=1}}== |
− | {| | + | GELOX/RT: '''<u>G</u>'''emcitabine, '''<u>L</u>'''-asparaginase, '''<u>O</u>'''xaliplatin, alternating with '''<u>R</u>'''adiation '''<u>T</u>'''herapy |
− | | | + | <div class="toccolours" style="background-color:#c8a2c8"> |
− | |[[Levels_of_Evidence#Evidence| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
+ | !style="width: 25%"|Study | ||
+ | !style="width: 25%"|Dates of enrollment | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1002/cncr.27752 Wang et al. 2012] |
− | |style="background-color:# | + | |2008-01 to 2011-07 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | | style="background-color:#f7fcfd" |ORR: 96% | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: total number of chemotherapy cycles was limited to 6.'' | |
− | '''[[Asparaginase (Elspar)]] | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Induction {{#subobject:ed4bb8|Variant=1}}=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 7 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 | ||
+ | '''21-day cycle for at least 2 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive therapy=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Radiotherapy==== | ||
+ | *[[External_beam_radiotherapy|IFRT]] to 5600 cGy in 28 fractions, 5 fractions per week | ||
+ | '''5.5-week course, followed within one week by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Consolidation=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 | *[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
*[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 7 | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 7 | ||
− | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> once on day 1 | + | *[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1 |
− | + | '''21-day cycle for up to 4 cycles''' | |
− | ''' | + | </div></div></div> |
− | |||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013 Jan 15;119(2):348-55. Epub 2012 Jul 18. [ | + | # Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013 Jan 15;119(2):348-55. Epub 2012 Jul 18. [https://doi.org/10.1002/cncr.27752 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22811078/ PubMed] |
==LVP "Sandwich" {{#subobject:b50432|Regimen=1}}== | ==LVP "Sandwich" {{#subobject:b50432|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
LVP: '''<u>L</u>'''-asparaginase, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisolone | LVP: '''<u>L</u>'''-asparaginase, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisolone | ||
− | + | <div class="toccolours" style="background-color:#c8a2c8"> | |
− | == | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | {| | + | !style="width: 25%"|Study |
− | | | + | !style="width: 25%"|Dates of enrollment |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1002/cncr.26629 Jiang et al. 2011] |
− | |style="background-color:# | + | |2008-07 to 2009-11 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | | style="background-color:#e0ecf4" |ORR: 84% | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Induction {{#subobject:5a27c1|Variant=1}}=== | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 5 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5 | ||
+ | '''21-day cycle for 2 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive therapy=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Radiotherapy==== | ||
+ | *[[External beam radiotherapy]] to the nasal cavity and surrounding sinuses, 5600 cGy in 28 fractions, once per day, five days per week | ||
+ | '''5.5-week course, followed in one week by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Consolidation=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 5 | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 5 | ||
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1 | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Prednisolone (Millipred)]] 100 mg PO once per day on days to 5 | + | ====Glucocorticoid therapy==== |
− | + | *[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5 | |
− | ''' | + | '''21-day cycle for up to 4 cycles''' |
− | + | </div></div></div> | |
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012 Jul 1;118(13):3294-301. Epub 2011 Dec 2. [ | + | # Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012 Jul 1;118(13):3294-301. Epub 2011 Dec 2. [https://doi.org/10.1002/cncr.26629 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22139825/ PubMed] ChicTR-TNC-00000394 |
− | + | ==MESA/RT {{#subobject:54b89d|Regimen=1}}== | |
− | == | + | MESA/RT: '''<u>M</u>'''ethotrexate, '''<u>E</u>'''toposide, '''<u>S</u>'''teroid (dexamethasone), PEG-'''<u>A</u>'''-sparaginase alternating with '''<u>R</u>'''adiation '''<u>T</u>'''therapy |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#c8a2c8"> |
+ | {| class="wikitable sortable" style="width: 80%; text-align:center;" | ||
+ | !style="width: 25%"|Study | ||
+ | !style="width: 25%"|Dates of enrollment | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763273/ Liang et al. 2016 (MESA-NKT2013)] | ||
+ | |2012-12 to 2015-01 | ||
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | |style="background-color:#e0ecf4"|ORR: 87% | ||
|- | |- | ||
− | |||
|} | |} | ||
− | SMILE: '''<u>S</u>'''teroid ( | + | <div class="toccolours" style="background-color:#eeeeee"> |
− | + | ===Induction {{#subobject:f98dcf|Variant=1}}=== | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Methotrexate (MTX)]] 2000 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4 | ||
+ | *[[Pegaspargase (Oncaspar)]] 2500 IU/m<sup>2</sup> IM once on day 5 | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> IV once per day on days 2 to 5 | ||
+ | '''21-day cycle for at least 3 cycles, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Definitive therapy=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Radiotherapy==== | ||
+ | *[[External_beam_radiotherapy|Radiation therapy]], 45 to 5000 cGy in 25 fractions | ||
+ | '''One course, followed by:''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Consolidation=== | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Methotrexate (MTX)]] 2000 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4 | ||
+ | *[[Pegaspargase (Oncaspar)]] 2500 IU/m<sup>2</sup> IM once on day 5 | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup> IV once per day on days 2 to 5 | ||
+ | '''21-day cycle for a maximum of 7 cycles''' | ||
+ | </div></div></div> | ||
+ | ===References=== | ||
+ | # '''MESA-NKT2013:''' Liang R, Gao GX, Chen JP, Wang JS, Wang XM, Zeng Y, Bai QX, Zhang T, Yang L, Dong BX, Gu HT, Shu MM, Hao CX, Wang JH, Zhang N, Chen XQ. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. Hematol Oncol. 2017 Dec;35(4):619-629. Epub 2016 Oct 10. [https://doi.org/10.1002/hon.2325 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763273/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/27723108/ PubMed] | ||
+ | ==SMILE {{#subobject:eaf2e1|Regimen=1}}== | ||
+ | SMILE: '''<u>S</u>'''teroid (Dexamethasone), '''<u>M</u>'''ethotrexate, '''<u>I</u>'''fosfamide, '''<u>L</u>'''-asparaginase, '''<u>E</u>'''toposide | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:cfe666|Variant=1}}=== | ===Regimen {{#subobject:cfe666|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2011.35.6287 Yamaguchi et al. 2011] |
− | |style="background-color:# | + | |2007-07 to 2009-10 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | |style="background-color:#e0ecf4"|ORR: 79% | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: After 2 cycles, patients could receive additional treatment with SMILE and/or other chemotherapy, with or without autologous/allogeneic stem cell transplant.'' | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 2 to 4 | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
*[[Methotrexate (MTX)]] 2000 mg/m<sup>2</sup> IV over 6 hours once on day 1 | *[[Methotrexate (MTX)]] 2000 mg/m<sup>2</sup> IV over 6 hours once on day 1 | ||
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 2 to 4 | *[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 2 to 4 | ||
*[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 8, 10, 12, 14, 16, 18, 20 | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 8, 10, 12, 14, 16, 18, 20 | ||
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4 | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *[[Leucovorin (Folinic acid)]] 15 mg IV or PO every 6 hours on days 2 to 4, beginning 30 hours after completion of methotrexate |
− | *[[Folinic acid | + | *[[Mesna (Mesnex)]] 300 mg/m<sup>2</sup> IV three times per day on days 2 to 4; first dose given together with ifosfamide, second dose given at 4 hours after start of ifosfamide, and third dose given 8 hours after start of ifosfamide |
− | *[[Mesna (Mesnex)]] 300 mg/m<sup>2</sup> IV three times per day on days 2 to 4; first dose given together with | + | *[[Filgrastim (Neupogen)]] (dose not specified) IV or SC once per day, starting on day 6, given until WBC count more than 5 x 10<sup>9</sup>/L |
− | *[[Filgrastim (Neupogen)]] (dose not specified) SC | + | *[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] prophylaxis recommended |
− | *[[Trimethoprim | + | '''28-day cycle for 2 cycles (see note)''' |
− | + | </div></div> | |
− | '''28-day cycle | ||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | # Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008 May;99(5):1016-20. Epub 2008 Feb 19. [ | + | # '''Phase 1:''' Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008 May;99(5):1016-20. Epub 2008 Feb 19. [https://doi.org/10.1111/j.1349-7006.2008.00768.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11158592/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18294294/ PubMed] content property of [https://hemonc.org HemOnc.org] |
− | # Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 Nov 20;29(33):4410-6. Epub 2011 Oct 11. [ | + | # Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R; NK-Cell Tumor Study Group. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 Nov 20;29(33):4410-6. Epub 2011 Oct 11. [https://doi.org/10.1200/jco.2011.35.6287 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21990393/ PubMed] UMIN000000712 |
=Consolidation after upfront therapy= | =Consolidation after upfront therapy= | ||
==VIPD {{#subobject:1de775|Regimen=1}}== | ==VIPD {{#subobject:1de775|Regimen=1}}== | ||
− | |||
− | |||
− | |||
− | |||
VIPD: '''<u>V</u>'''P-16 (Etoposide), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin), '''<u>D</u>'''examethasone | VIPD: '''<u>V</u>'''P-16 (Etoposide), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin), '''<u>D</u>'''examethasone | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:76171b|Variant=1}}=== | ===Regimen {{#subobject:76171b|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | | | + | !style="width: 33%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2009.23.8592 Kim et al. 2009 (CISL 2004-10-08)] |
− | |style="background-color:# | + | |2006-04 to 2007-10 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1111/ejh.12405 Tsai et al. 2014 (T1405)] |
− | |style="background-color:# | + | |2006-05 to 2009-09 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Details here are from CISL 2004-10-08.'' |
− | + | <div class="toccolours" style="background-color:#cbd5e8"> | |
+ | ====Preceding treatment==== | ||
+ | *CISL 2004-10-08: [[#Cisplatin_.26_RT|Cisplatin & RT]] induction | ||
+ | *T1405: [[#DEP_.26_RT|DEP & RT]] induction | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 to 3 | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 to 3 | ||
− | *[[Ifosfamide (Ifex)]] 1200 mg/m<sup>2</sup> IV over | + | *[[Ifosfamide (Ifex)]] 1200 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3 |
− | *[[Cisplatin (Platinol)]] 33 mg/m<sup>2</sup> IV over | + | *[[Cisplatin (Platinol)]] 33 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3 |
− | *[[Dexamethasone (Decadron)]] 40 mg PO | + | ====Glucocorticoid therapy==== |
− | + | *[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 1 to 4 | |
− | ====Supportive | + | ====Supportive therapy==== |
*[[Mesna (Mesnex)]] 240 mg/m<sup>2</sup> IV over 15 minutes once per day on days 1 to 3 | *[[Mesna (Mesnex)]] 240 mg/m<sup>2</sup> IV over 15 minutes once per day on days 1 to 3 | ||
− | *[[ | + | *[[:Category:Granulocyte colony-stimulating factors|G-CSF]] given for grade 3 or 4 neutropenia |
− | + | '''21-day cycle for up to 3 cycles''' | |
− | '''21-day cycle | + | </div></div> |
− | |||
===References=== | ===References=== | ||
− | # Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, | + | # '''CISL 2004-10-08:''' Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS; Consortium for Improving Survival of Lymphoma. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009 Dec 10;27(35):6027-32. Epub 2009 Nov 2. [https://doi.org/10.1200/jco.2009.23.8592 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/19884539/ PubMed] [https://clinicaltrials.gov/study/NCT00418535 NCT00418535] |
− | # Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7. Epub 2014 Oct 10. [ | + | #'''T1405:''' Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7. Epub 2014 Oct 10. [https://doi.org/10.1111/ejh.12405 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24957163/ PubMed] [https://clinicaltrials.gov/study/NCT00292695 NCT00292695] |
− | + | =Relapsed or refractory= | |
− | =Relapsed | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | == | + | ==L-Asparaginase, Vincristine, Prednisolone {{#subobject:1ba9b6|Regimen=1}}== |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
LVP: '''<u>L</u>'''-asparaginase, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisolone | LVP: '''<u>L</u>'''-asparaginase, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisolone | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:651a7|Variant=1}}=== | ===Regimen {{#subobject:651a7|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1007/bf02983387 Yong et al. 2003] |
− | | | + | |1992-03 to 2002-03 |
− | style="background | + | |style="background-color:#ffffbe"|Phase 2, fewer than 20 patients |
− | + | | style="background-color:#e0ecf4" |ORR: 83% | |
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
− | '' | + | ''Note: Regimen details are from a review article; original article is not available through PubMed'' |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 5 | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 1 to 5 | ||
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1 | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1 | ||
− | *[[Prednisolone (Millipred)]] 100 mg PO once per day on days to 5 | + | ====Glucocorticoid therapy==== |
− | + | *[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5 | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003 Aug;78(2):163-7. [https:// | + | # Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003 Aug;78(2):163-7. [https://doi.org/10.1007/bf02983387 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12953813/ PubMed] |
− | |||
==SMILE {{#subobject:924b1a|Regimen=1}}== | ==SMILE {{#subobject:924b1a|Regimen=1}}== | ||
− | + | SMILE: '''<u>S</u>'''teroid (Dexamethasone), '''<u>M</u>'''ethotrexate, '''<u>I</u>'''fosfamide, '''<u>L</u>'''-asparaginase, '''<u>E</u>'''toposide | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | SMILE: '''<u>S</u>'''teroid ( | ||
− | |||
===Regimen {{#subobject:aa2ac|Variant=1}}=== | ===Regimen {{#subobject:aa2ac|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2011.35.6287 Yamaguchi et al. 2011] |
− | |style="background-color:# | + | |2007-07 to 2009-10 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | | style="background-color:#e0ecf4" |ORR: 79% | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: After 2 cycles, patients could receive additional treatment with SMILE and/or other chemotherapy, with or without autologous/allogeneic stem cell transplant.'' | |
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 2 to 4 | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
*[[Methotrexate (MTX)]] 2000 mg/m<sup>2</sup> IV over 6 hours once on day 1 | *[[Methotrexate (MTX)]] 2000 mg/m<sup>2</sup> IV over 6 hours once on day 1 | ||
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 2 to 4 | *[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 2 to 4 | ||
*[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 8, 10, 12, 14, 16, 18, 20 | *[[Asparaginase (Elspar)]] 6000 units/m<sup>2</sup> IV once per day on days 8, 10, 12, 14, 16, 18, 20 | ||
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4 | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *[[Leucovorin (Folinic acid)]] 15 mg IV or PO every 6 hours on days 2 to 4, beginning 30 hours after completion of methotrexate |
− | *[[Folinic acid | + | *[[Mesna (Mesnex)]] 300 mg/m<sup>2</sup> IV three times per day on days 2 to 4; first dose given together with [[Ifosfamide (Ifex)]], second dose given at 4 hours after start of ifosfamide, and third dose given 8 hours after start of ifosfamide |
− | *[[Mesna (Mesnex)]] 300 mg/m<sup>2</sup> IV three times per day on days 2 to 4; first dose given together with [[Ifosfamide (Ifex)]], second dose given at 4 hours after start of | + | *[[Filgrastim (Neupogen)]] (dose not specified) IV or SC once per day, starting on day 6, given until WBC count more than 5 x 10<sup>9</sup>/L |
− | *[[Filgrastim (Neupogen)]] (dose not specified) SC | + | *[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] prophylaxis recommended |
− | *[[Trimethoprim | + | '''28-day cycle for 2 cycles (see note)''' |
− | + | </div></div> | |
− | '''28-day cycle | ||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
− | + | # Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R; NK-Cell Tumor Study Group. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 Nov 20;29(33):4410-6. Epub 2011 Oct 11. [https://doi.org/10.1200/jco.2011.35.6287 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/21990393/ PubMed] | |
− | # Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 Nov 20;29(33):4410-6. Epub 2011 Oct 11. [ | + | [[Category:Extranodal NK- and T-cell lymphoma, nasal type regimens]] |
− | + | [[Category:Disease-specific pages]] | |
− | [[Category: | + | [[Category:T-cell lymphomas]] |
− | [[Category: | ||
− | [[Category: |
Latest revision as of 12:19, 15 July 2024
Section editor | |
---|---|
Bhagirathbhai Dholaria, MBBS Vanderbilt University Nashville, TN, USA |
Most of these regimens are specific to the nasal type of ENKTCL. For more generic NKTCL regimens, please see this page.
10 regimens on this page
10 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- 2015: d'Amore et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - T-cell Lymphomas.
Untreated
Cisplatin & RT
Cisplatin & RT: Cisplatin & Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Kim et al. 2009 (CISL 2004-10-08) | 2006-04 to 2007-10 | Phase 2 | ORR: 83% |
Chemotherapy
- Cisplatin (Platinol) 30 mg/m2 IV once per day on days 1, 8, 15, 22
Radiotherapy
- Concurrent radiation therapy to the primary tumor, 1.8 to 200 cGy fractions (median total dose: 4000 cGy), given 5 times per week.
4-week course
Subsequent treatment
- VIPD consolidation, 3 to 5 weeks after the last dose of cisplatin
References
- CISL 2004-10-08: Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS; Consortium for Improving Survival of Lymphoma. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009 Dec 10;27(35):6027-32. Epub 2009 Nov 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00418535
DEP & RT
DEP & RT: Dexamethasone, Etoposide, Platinol (Cisplatin), Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Tsai et al. 2014 (T1405) | 2006-05 to 2009-09 | Phase 2 | ORR: 81% |
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg/m2/day IV on days 1 to 3
Chemotherapy
- Etoposide (Vepesid) 75 mg/m2 IV over 60 minutes once per day on days 1 to 3
- Cisplatin (Platinol) 75 mg/m2 IV over 4 hours once on day 1
Radiotherapy
- Concurrent radiation therapy to the primary tumor: 5040 cGy in 28 fractions
28-day cycle for 2 cycles
Subsequent treatment
- VIPD consolidation
References
- T1405: Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7. Epub 2014 Oct 10. link to original article contains dosing details on CT.gov PubMed NCT00292695
DeVIC & RT
DeVIC & RT: Dexamethasone, VP-16 (Etoposide), Ifosfamide, Carboplatin, Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Yamaguchi et al. 2009 (JCOG0211) | 2003-09 to 2006-12 | Phase 1/2 | ORR: 81% |
Note: this is the recommended dose level used in the phase 2 portion.
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg IV once per day on days 1 to 3
Chemotherapy
- Etoposide (Vepesid) 67 mg/m2 IV over 2 hours once per day on days 1 to 3, 22 to 24, 43 to 45
- Ifosfamide (Ifex) 1000 mg/m2 IV over 3 hours once per day on days 1 to 3, 22 to 24, 43 to 45
- Carboplatin (Paraplatin) 200 mg/m2 IV over 30 minutes once per day on days 1, 22, 43
Supportive therapy
- Filgrastim (Neupogen) (dose/route/schedule not specified) started for WBC count less than 2 x 109/L or ANC less than 1000/μL; discontinued if WBC count more than 5 x 109/L
Radiotherapy
Started simultaneously with the beginning of cycle 1 of chemotherapy
- Concurrent radiation therapy by the following stage-based criteria:
- Stage IE: 200 cGy fractions x 25 fractions (total dose: 5000 cGy)
- Stage IIE: 180 cGy fractions x 28 fractions (total dose: 5040 cGy)
9-week course
References
- JCOG0211: Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009 Nov 20;27(33):5594-600. Epub 2009 Oct 5. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- Update: Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Hotta T, Tsukasaki K, Oshimi K. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012 Nov 10;30(32):4044-6. Epub 2012 Oct 8. link to original article PubMed
GELOX/RT
GELOX/RT: Gemcitabine, L-asparaginase, Oxaliplatin, alternating with Radiation Therapy
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Wang et al. 2012 | 2008-01 to 2011-07 | Phase 2 | ORR: 96% |
Note: total number of chemotherapy cycles was limited to 6.
Induction
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 1 to 7
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
21-day cycle for at least 2 cycles, followed by:
Definitive therapy
Radiotherapy
- IFRT to 5600 cGy in 28 fractions, 5 fractions per week
5.5-week course, followed within one week by:
Consolidation
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 1 to 7
- Oxaliplatin (Eloxatin) 130 mg/m2 IV once on day 1
21-day cycle for up to 4 cycles
References
- Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013 Jan 15;119(2):348-55. Epub 2012 Jul 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed
LVP "Sandwich"
LVP: L-asparaginase, Vincristine, Prednisolone
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Jiang et al. 2011 | 2008-07 to 2009-11 | Phase 2 | ORR: 84% |
Induction
Chemotherapy
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 1 to 5
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
Glucocorticoid therapy
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 5
21-day cycle for 2 cycles, followed by:
Definitive therapy
Radiotherapy
- External beam radiotherapy to the nasal cavity and surrounding sinuses, 5600 cGy in 28 fractions, once per day, five days per week
5.5-week course, followed in one week by:
Consolidation
Chemotherapy
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 1 to 5
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
Glucocorticoid therapy
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 5
21-day cycle for up to 4 cycles
References
- Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012 Jul 1;118(13):3294-301. Epub 2011 Dec 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed ChicTR-TNC-00000394
MESA/RT
MESA/RT: Methotrexate, Etoposide, Steroid (dexamethasone), PEG-A-sparaginase alternating with Radiation Ttherapy
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Liang et al. 2016 (MESA-NKT2013) | 2012-12 to 2015-01 | Phase 2 | ORR: 87% |
Induction
Chemotherapy
- Methotrexate (MTX) 2000 mg/m2 IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 2 to 4
- Pegaspargase (Oncaspar) 2500 IU/m2 IM once on day 5
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg/m2 IV once per day on days 2 to 5
21-day cycle for at least 3 cycles, followed by:
Definitive therapy
Consolidation
Chemotherapy
- Methotrexate (MTX) 2000 mg/m2 IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 2 to 4
- Pegaspargase (Oncaspar) 2500 IU/m2 IM once on day 5
Glucocorticoid therapy
- Dexamethasone (Decadron) 20 mg/m2 IV once per day on days 2 to 5
21-day cycle for a maximum of 7 cycles
References
- MESA-NKT2013: Liang R, Gao GX, Chen JP, Wang JS, Wang XM, Zeng Y, Bai QX, Zhang T, Yang L, Dong BX, Gu HT, Shu MM, Hao CX, Wang JH, Zhang N, Chen XQ. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. Hematol Oncol. 2017 Dec;35(4):619-629. Epub 2016 Oct 10. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
SMILE
SMILE: Steroid (Dexamethasone), Methotrexate, Ifosfamide, L-asparaginase, Etoposide
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Yamaguchi et al. 2011 | 2007-07 to 2009-10 | Phase 2 | ORR: 79% |
Note: After 2 cycles, patients could receive additional treatment with SMILE and/or other chemotherapy, with or without autologous/allogeneic stem cell transplant.
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg IV or PO once per day on days 2 to 4
Chemotherapy
- Methotrexate (MTX) 2000 mg/m2 IV over 6 hours once on day 1
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 2 to 4
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 8, 10, 12, 14, 16, 18, 20
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 2 to 4
Supportive therapy
- Leucovorin (Folinic acid) 15 mg IV or PO every 6 hours on days 2 to 4, beginning 30 hours after completion of methotrexate
- Mesna (Mesnex) 300 mg/m2 IV three times per day on days 2 to 4; first dose given together with ifosfamide, second dose given at 4 hours after start of ifosfamide, and third dose given 8 hours after start of ifosfamide
- Filgrastim (Neupogen) (dose not specified) IV or SC once per day, starting on day 6, given until WBC count more than 5 x 109/L
- Trimethoprim-Sulfamethoxazole (Bactrim DS) prophylaxis recommended
28-day cycle for 2 cycles (see note)
References
- Phase 1: Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008 May;99(5):1016-20. Epub 2008 Feb 19. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed content property of HemOnc.org
- Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R; NK-Cell Tumor Study Group. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 Nov 20;29(33):4410-6. Epub 2011 Oct 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed UMIN000000712
Consolidation after upfront therapy
VIPD
VIPD: VP-16 (Etoposide), Ifosfamide, Platinol (Cisplatin), Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Kim et al. 2009 (CISL 2004-10-08) | 2006-04 to 2007-10 | Phase 2 |
Tsai et al. 2014 (T1405) | 2006-05 to 2009-09 | Phase 2 |
Details here are from CISL 2004-10-08.
Preceding treatment
- CISL 2004-10-08: Cisplatin & RT induction
- T1405: DEP & RT induction
Chemotherapy
- Etoposide (Vepesid) 100 mg/m2 IV over 90 minutes once per day on days 1 to 3
- Ifosfamide (Ifex) 1200 mg/m2 IV over 60 minutes once per day on days 1 to 3
- Cisplatin (Platinol) 33 mg/m2 IV over 60 minutes once per day on days 1 to 3
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg IV or PO once per day on days 1 to 4
Supportive therapy
- Mesna (Mesnex) 240 mg/m2 IV over 15 minutes once per day on days 1 to 3
- G-CSF given for grade 3 or 4 neutropenia
21-day cycle for up to 3 cycles
References
- CISL 2004-10-08: Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS; Consortium for Improving Survival of Lymphoma. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009 Dec 10;27(35):6027-32. Epub 2009 Nov 2. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00418535
- T1405: Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7. Epub 2014 Oct 10. link to original article PubMed NCT00292695
Relapsed or refractory
L-Asparaginase, Vincristine, Prednisolone
LVP: L-asparaginase, Vincristine, Prednisolone
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Yong et al. 2003 | 1992-03 to 2002-03 | Phase 2, fewer than 20 patients | ORR: 83% |
Note: Regimen details are from a review article; original article is not available through PubMed
Chemotherapy
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 1 to 5
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
Glucocorticoid therapy
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 5
References
- Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003 Aug;78(2):163-7. link to original article PubMed
SMILE
SMILE: Steroid (Dexamethasone), Methotrexate, Ifosfamide, L-asparaginase, Etoposide
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Yamaguchi et al. 2011 | 2007-07 to 2009-10 | Phase 2 | ORR: 79% |
Note: After 2 cycles, patients could receive additional treatment with SMILE and/or other chemotherapy, with or without autologous/allogeneic stem cell transplant.
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg IV or PO once per day on days 2 to 4
Chemotherapy
- Methotrexate (MTX) 2000 mg/m2 IV over 6 hours once on day 1
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 2 to 4
- Asparaginase (Elspar) 6000 units/m2 IV once per day on days 8, 10, 12, 14, 16, 18, 20
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 2 to 4
Supportive therapy
- Leucovorin (Folinic acid) 15 mg IV or PO every 6 hours on days 2 to 4, beginning 30 hours after completion of methotrexate
- Mesna (Mesnex) 300 mg/m2 IV three times per day on days 2 to 4; first dose given together with Ifosfamide (Ifex), second dose given at 4 hours after start of ifosfamide, and third dose given 8 hours after start of ifosfamide
- Filgrastim (Neupogen) (dose not specified) IV or SC once per day, starting on day 6, given until WBC count more than 5 x 109/L
- Trimethoprim-Sulfamethoxazole (Bactrim DS) prophylaxis recommended
28-day cycle for 2 cycles (see note)
References
- Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R; NK-Cell Tumor Study Group. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 Nov 20;29(33):4410-6. Epub 2011 Oct 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed